Literature DB >> 11676196

Antiischemic properties of fasudil in experimental models of vasospastic angina.

S Sato1, I Ikegaki, T Asano, H Shimokawa.   

Abstract

We studied the antiischemic properties of fasudil, a Rho-kinase inhibitor, in conscious rabbits with coronary vasospasm induced by vasopressin and endothelin. Pretreatment with fasudil (0.3 and 3 mg/kg) attenuated the maximum elevation of the T-wave elicited by endothelin. Pretreatment with fasudil inhibited the T-wave elevation elicited by vasopressin. Fasudil and hydroxy fasudil, an active metabolite of fasudil, relaxed the endothelin-, U-46619-, 5-hydroxytryptamine- or histamine-induced contraction in swine coronary arterial strips. Fasudil and hydroxy fasudil significantly prevented the reduction in coronary flow by vasopressin in the Langendorff perfused rat heart. Fasudil was effective in protecting the heart against vasopressin and endothelin-induced myocardial ischemic change in conscious rabbits, and this beneficial effect can be attributed to its action of ameliorating the severe contraction of arteries. The inhibition of Rho-kinase may have implications for the development of novel therapeutic strategies for vasospastic angina in patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11676196     DOI: 10.1254/jjp.87.34

Source DB:  PubMed          Journal:  Jpn J Pharmacol        ISSN: 0021-5198


  5 in total

Review 1.  MECHANISTIC INSIGHTS OF CORONARY VASOSPASM AND NEW THERAPEUTIC APPROACHES.

Authors:  Shu-ichi Saitoh; Yasuchika Takeishi; Yukio Maruyama
Journal:  Fukushima J Med Sci       Date:  2015-06-11

Review 2.  Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases.

Authors:  Ming Dong; Bryan P Yan; James K Liao; Yat-Yin Lam; Gabriel W K Yip; Cheuk-Man Yu
Journal:  Drug Discov Today       Date:  2010-06-25       Impact factor: 7.851

3.  A combination of increased Rho kinase activity and N-terminal pro-B-type natriuretic peptide predicts worse cardiovascular outcome in patients with acute coronary syndrome.

Authors:  Ming Dong; James K Liao; Bryan Yan; Ruijie Li; Mang Zhang; Cheuk-Man Yu
Journal:  Int J Cardiol       Date:  2012-08-24       Impact factor: 4.164

4.  Antiatherogenic and Anti-Ischemic Properties of Traditional Chinese Medicine Xinkeshu via Endothelial Protecting Function.

Authors:  Xu Tao; Peng Jing-Bo; Zhang Wen-Tong; Zhao Xin; Zhang Tao-Tao; Yang Shi-Jun; Fang Lei; Zou Zhong-Mei; Cai Da-Yong
Journal:  Evid Based Complement Alternat Med       Date:  2011-10-10       Impact factor: 2.629

Review 5.  RhoGTPase in Vascular Disease.

Authors:  Derek Strassheim; Evgenia Gerasimovskaya; David Irwin; Edward C Dempsey; Kurt Stenmark; Vijaya Karoor
Journal:  Cells       Date:  2019-06-06       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.